

## **Bahasa Indonesia**

### **English Language (12pt, bold, 18 Words Tittle)**

#### **1. Abstrak (Indonesia)**

Abstract content {max 250 words}

**Kata Kunci:** *max five words*

#### **2. Abstract**

Abstract content {max 250 words}

**Keywords:** *max five words*

#### **3. Introduction**

In Introduction, Authors should state the objectives of the work at the end of introduction section. Before the objective, Authors should provide an adequate background (maximum 1 paragraph), and very short literatures survey/review in order to record the existing solutions/method, to show which is the best of previous researches, to show the main limitation of the previous researches, to show what do you hope to achieve (to solve the limitation), and to show the scientific merit or novelties of the paper. Avoid a detailed literature survey or a summary of the results. Do not describe literatures survey/review as author by author but should be presented as group of articles per method or topic reviewed which refers to some literatures.

One of examples of novelty statement or the gap analysis statement in the end of Introduction section (after state of the art of previous research survey) as follow:

*"..... (short summary of background) ..... (put here state of the art or overview of previous researches similar to this research)..... A few researchers focused on ..... There have been limited studies concerned on ..... Therefore, this*

---

Corresponding author:

Email:

**Received:** 2 March 2022. **Revised:** 24 June 2022. **Published:** 6 December 2022

*research intends to ..... The objectives of this research are ....."*

or

*"..... (short summary of background) ..... (put here state of the art or overview of previous researches similar to this research) ..... A few researchers focused on ..... There is no researcher concerned on ..... Therefore, this research focuses on ..... Therefore, this research is aimed to ....."*

etc.

## **4. Experimental Section**

### **4.1. Materials**

According to Engelmores and Morgan [1], manuscript content should, in general, be organized in the following order: Title; Authors Name; Authors Affiliation; Abstract; Keywords; Introduction; Materials and Methods; Results and Discussion; Conclusions; Acknowledgments; and References. Manuscript document submitted to this journal (in one MS Word or PDF file) should be arranged as follow: (a) Bodytext of manuscript article (from Title to References, without tables and figures); (b) Figure Captions and Table Captions; (c) Figures (one figure per page); and (d) Tables (one table per page). Please include a Covering Letter in a separated document file containing your summary of scientific finding and uploaded in Supplementary Files.

### **4.2. Methods**

According to Engelmores and Morgan [1], manuscript content should, in general, be organized in the following order: Title; Authors Name; Authors Affiliation; Abstract; Keywords; Introduction; Materials and Methods; Results and Discussion; Conclusions; Acknowledgments; and References. Manuscript document submitted to this journal (in one MS Word or PDF file) should be arranged as follow: (a) Bodytext of manuscript article (from Title to References, without tables and figures); (b) Figure Captions and Table Captions; (c) Figures (one figure per page); and (d) Tables (one table per page). Please include a Covering Letter in a separated document file containing your summary

of scientific finding and uploaded in Supplementary Files.

## **5. Results and Discussion**

### **5.1. Section Headings**

Three levels of heading are allowed as follows: (a) Level 1 (Heading1 format) - 12pt, Times bold, left justified; (b) Level 2 (Heading2 format) - 12pt, Times bold, left justified; and (c) Level 3 (Heading3 format) - 12pt, Times bold italic, left justified.

### **5.2. Body Text**

The body of the text is a set of body text paragraphs defined as follows: (a) 12pt Times New Roman; (b) One-half space, defined as 12pt; (c) Spacing after the heading is 3pt; (d) Spacing before the new heading is 12pt; (e) Indentation for the first line is 1 cm.

### **5.3. Bullets**

Bullet and numbering within body text are not allowed. All sentence should be typed as descriptive paragraph format.

### **5.4. Tables**

Tables are sequentially numbered with the table title and number above the table. Tables should be centered in the column OR on the page. Tables should be followed by a line space (12pt). Elements of a table should be single-spaced, however double spacing can be used to show groupings of data or to separate parts within the table. Table headings should be in 10pt bold. Tables are referred in the text by the table number without location (above, below, following, etc.), e.g.: Table 1. Do not show vertical line in the table. There is only horizontal line should be shown within the table.

### 5.5. Figures

Figures are sequentially numbered commencing at 1 with the figure title and number below the figure as shown in Figure 1. Detailed recommendations for figures are as follows: (a) Ensure that figures are clear and legible with typed letterings. (b) Black & white or colored figures are allowed. (c) If a figure spans two columns, it should be placed at the top or bottom of a page. (d) Hard copy illustrations should, preferably, be scanned and included in the electronic version of the submission in an appropriate format as follows: BMP - Microsoft bitmap file, WMF - Windows Metafile Format, EPS - Encapsulated Postscript. (e) If figures cannot be scanned, the original should be placed in its location within the manuscript using wax or colorless glue. (f) The following files are permissible: Microsoft Graph, Microsoft Draw.

### 5.6. Equations

Equations should be numbered serially within parentheses as shown in Equation (1). Equation should be prepared using MS Equation Editor (not in image format). The equation number is to be placed at the extreme right side.

$$\int_0^{r_2} F(r, \varphi) dr d\varphi = [\sigma r_2 / (2\mu_0)] \cdot \int_0^\infty \exp(-\lambda |z_j - z_i|) \lambda^{-1} J_1(\lambda r_2) J_0(\lambda r_i) d\lambda. \quad (1)$$

### 5.7. Units, Abbreviations and Symbols

Metric units are preferred. Define abbreviations and symbols at the first time as they are introduced in the text. Definition of symbols should be presented in paragraph form, not as list bulleted.

## 6. Conclusion

Conclusions should only answer the objectives of the research. Tells how your work advances the field from the present state of knowledge. Without clear Conclusions, reviewers and readers will find it difficult to judge the work, and whether or not it merits publication in the journal. Do not repeat the Abstract, or just list experimental results. Provide a clear scientific justification for your work, and indicate possible

applications and extensions. This conclusion should be provided as a paragraph. You should also suggest future experiments and/or point out those that are underway.

## 7. Acknowledgement

Recognize those who helped in the research, **especially funding supporter of your research financially**. Include individuals who have assisted you in your study: Advisors, Financial supporters, or may another supporter, i.e. Proofreaders, Typists, and Suppliers, who may have given materials. Do not acknowledge one of the authors names.

## 8. References

Cite the main scientific publications on which your work is based. Cite only items that you have read. Do not inflate the manuscript with too many references. Avoid excessive self-citations. Avoid excessive citations of publications from the same region. Check each reference against the original source (authors name, volume, issue, year, DOI Number). Please use Reference Manager Applications like EndNote, Mendeley, Zotero, etc. Use other published articles in the same journal as models. **The minimum number of references should be 15 references.**

References list MUST follow VANCOUVER.

1. Mackowiak PA, Chervenak FA, Grünebaum A. Defining Fever. *Open Forum Infect Dis.* 2021 Jun 1;8(6).
2. Mota CMD, Madden CJ. Neural circuits mediating circulating interleukin-1 $\beta$ -evoked fever in the absence of prostaglandin E2. *Brain Behav Immun.* 2022;103(July 2022):109–21.
3. Rose-John S. Interleukin-6 signalling in health and disease. *F1000Res.* 2020;9.
4. You K, Gu H, Yuan Z, Xu X. Tumor Necrosis Factor Alpha Signaling and Organogenesis. Vol. 9, *Frontiers in Cell and Developmental Biology.* Frontiers Media S.A.; 2021.
5. Eskilsson A, Shionoya K, Engblom D, Blomqvist A. Fever during localized inflammation in mice is elicited by a humoral pathway and depends on brain endothelial interleukin-1 and interleukin-6 signaling and central EP3receptors. *Journal of Neuroscience.* 2021 Jun 16;41(24):5206–18.

6. Cimpello LB, Goldman DL, Khine H. Fever Pathophysiology. *Clin Pediatr Emerg Med.* 2000;1:84–93.
7. Mota-Rojas D, Wang D, Titto CG, Gómez-Prado J, Carvajal-De la Fuente V, Ghezzi M, et al. Pathophysiology of fever and application of infrared thermography (Irt) in the detection of sick domestic animals: Recent advances. Vol. 11, *Animals.* MDPI AG; 2021.
8. Prajitha N, Athira SS, Mohanan P V. Pyrogens, a polypeptide produces fever by metabolic changes in hypothalamus: Mechanisms and detections. Vol. 204, *Immunology Letters.* Elsevier B.V.; 2018. p. 38–46.
9. Ames NJ, Powers JH, Ranucci A, Gartrell K, Yang L, VanRaden M, et al. A systematic approach for studying the signs and symptoms of fever in adult patients: The fever assessment tool (FAST). *Health Qual Life Outcomes.* 2017 Apr 27;15(1).
10. Ülger F, Pehlivanlar Küçük M, Öztürk ÇE, Aksoy İ, Küçük AO, Murat N. Non-infectious Fever After Acute Spinal Cord Injury in the Intensive Care Unit. *Journal of Spinal Cord Medicine.* 2019 May 4;42(3):310–7.
11. Cachot JT, Manuel J, Azcona B, Falp JB, Ilari HC. Classic fever of unknown origin: Analysis of a cohort of 87 patients according to the definition with qualitative study criterion. Vol. 156, *Medicina Clínica.* 2021.
12. Wright WF, Mulders-Manders CM, Auwaerter PG, Bleeker-Rovers CP. Fever of Unknown Origin (FUO) – A Call for New Research Standards and Updated Clinical Management. Vol. 135, *American Journal of Medicine.* Elsevier Inc.; 2022. p. 173–8.
13. World Health Organization. <https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue>. 2022. p. 1–1 Dengue and severe dengue.
14. Yudhistira AW. <https://databoks.katadata.co.id/datapublish/2022/03/01/musim-penghujan-terjadi-13776-kasus-dbd-pada-awal-2022>. 2022. p. 1–1 Rainy season, there will be 13,776 cases of dengue fever in early 2022.
15. Worldometer. <https://www.worldometers.info/coronavirus/>. 2022. p. 1–1 COVID-19 Coronavirus Pandemic.




Figure 1 Visualization Molecular Docking A: Acetaminophen; B: Alanine; C: HEFS; D: Lombricine.

## 9. Tables

Table 1. Table caption and description

Table header	Table header	Table header
Table content	Table content	Table content



Table content

Table content

Table content

---